You are currently viewing Biomatrix Features Relevant to Bifurcational Stenting and the LEADERS Bifurcation Substudy

Biomatrix Features Relevant to Bifurcational Stenting and the LEADERS Bifurcation Substudy

Biomatrix Features Relevant to Bifurcational Stenting and the LEADERS Bifurcation Substudy

European Bifurcation Club 2010 – EBC 2010 – Budapest, Hungary

New DES and bifurcation stenting

Biomatrix Features Relevant to Bifurcational Stenting and the LEADERS Bifurcation Substudy

Author: Carlo Di Mario, Nicolas Foin, Imperial College London, UK

 

BIOLIMUS A9 ELUTING BIOMATRIX STENT

  • Biolimus is a semi-synthetic sirolimus analogue with 10x higher lipophilicity and similar potency as sirolimus.
  • Biolimus is immersed into a biodegradable polymer, polylactic acid, and applied solely to the abluminal stent surface
  • Biolimus is co-released with polylactic acid that completely desolves into carbon dioxide and water after a 6-9 months period.
  • The same coating and drug has been successfully used in bifurcational trials with the dedicated self- expanding DEVAX platform
  • The stainless steel stent platform has a strut thickness of 120 μm with a quadrature link design.

CONCLUSION

  • The Biomatrix Flex stent offers a large opening when dilated through the struts, sufficient to fit almost all coronary anatomies
  • Biolimus eluting stent appears to offer an advantage in treating patients with bifurcational lesions
  • Larger cohorts of prospectively collected data as well as mechanistic insights are needed to confirm these findings.

 

DOWNLOAD HERE

Leave a Reply